Increasing Access to Nonprescription Drugs

This hybrid public meeting, convened by the Duke-Margolis Institute for Health Policy under a cooperative agreement with the U.S. Food and Drug Administration, will convene drug developers, health care providers, patient and consumer representatives, and other relevant stakeholders to discuss opportunities to increase access to nonprescription drugs. The meeting will focus on the new drug application process for nonprescription drugs, which includes direct-to-nonprescription applications, prescription-to-nonprescription “switch” applications, and applications with Additional Conditions for Nonprescription Use. Participants will also discuss practical considerations related to access, innovative strategies to increase access, and how increased access may affect individual and public health outcomes.

This event is supported by the Food and Drug Administration (FDA) of the U.S. Department of Health and Human Services (HHS) as part of a financial assistance award U01FD008451 totaling $1,399,999 with 100 percent funded by FDA/HHS. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by FDA/HHS, or the U.S. Government.